Mid‑Cap Insight: Sichuan Kelun Pharmaceutical’s 2026 Stock, P/E, & Diversified Portfolio
Explore Sichuan Kelun Pharmaceutical’s latest 2026 data: mid‑cap stock, $10.9B market cap, high P/E, diversified pharma products, and board update insights.
2 minutes to read